BLISS GVS PHARMA
|
BLISS GVS PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 7.21 | 6.80 | 1.45 | 6.64 | 9.43 |
| CEPS(Rs) | 10.31 | 9.16 | 3.90 | 8.84 | 10.46 |
| DPS(Rs) | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 |
| Book NAV/Share(Rs) | 91.65 | 84.01 | 78.01 | 77.41 | 71.32 |
| Tax Rate(%) | 30.20 | 27.66 | 57.30 | 28.96 | 26.14 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 19.34 | 15.61 | 15.83 | 18.48 | 17.89 |
| EBIT Margin(%) | 16.07 | 15.49 | 7.88 | 19.29 | 19.81 |
| Pre Tax Margin(%) | 15.17 | 14.11 | 7.25 | 18.04 | 18.71 |
| PAT Margin (%) | 10.59 | 10.21 | 3.09 | 12.82 | 13.82 |
| Cash Profit Margin (%) | 14.02 | 12.69 | 5.41 | 15.80 | 15.64 |
| Performance Ratios | |||||
| ROA(%) | 6.89 | 6.78 | 2.12 | 7.03 | 9.86 |
| ROE(%) | 8.89 | 9.11 | 2.88 | 9.64 | 13.79 |
| ROCE(%) | 12.15 | 12.22 | 6.37 | 12.49 | 17.02 |
| Asset Turnover(x) | 0.65 | 0.66 | 0.68 | 0.55 | 0.71 |
| Sales/Fixed Asset(x) | 1.66 | 1.87 | 2.38 | 2.06 | 3.09 |
| Working Capital/Sales(x) | 1.18 | 1.49 | 1.37 | 1.03 | 1.28 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.60 | 0.53 | 0.42 | 0.49 | 0.32 |
| Receivable days | 187.07 | 188.89 | 209.14 | 319.89 | 267.05 |
| Inventory Days | 52.48 | 55.12 | 54.42 | 54.72 | 40.11 |
| Payable days | 70.38 | 81.40 | 77.87 | 90.85 | 70.02 |
| Valuation Parameters | |||||
| PER(x) | 15.63 | 10.47 | 53.04 | 14.86 | 10.69 |
| PCE(x) | 10.92 | 7.78 | 19.72 | 11.16 | 9.64 |
| Price/Book(x) | 1.23 | 0.85 | 0.99 | 1.28 | 1.41 |
| Yield(%) | 0.44 | 0.70 | 0.65 | 0.51 | 0.50 |
| EV/Net Sales(x) | 1.37 | 0.98 | 0.97 | 1.72 | 1.53 |
| EV/Core EBITDA(x) | 5.86 | 5.46 | 4.84 | 7.72 | 6.51 |
| EV/EBIT(x) | 8.49 | 6.33 | 12.31 | 8.91 | 7.74 |
| EV/CE(x) | 1.00 | 0.75 | 0.65 | 0.92 | 1.03 |
| M Cap / Sales | 1.53 | 0.99 | 1.07 | 1.76 | 1.51 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 2.48 | 0.55 | 29.50 | -16.26 | -23.29 |
| Core EBITDA Growth(%) | 32.75 | -9.83 | 16.51 | -20.86 | -16.78 |
| EBIT Growth(%) | 6.31 | 97.66 | -47.11 | -18.43 | -26.72 |
| PAT Growth(%) | 6.31 | 231.80 | -68.74 | -22.34 | -24.80 |
| EPS Growth(%) | 5.94 | 368.98 | -78.15 | -29.58 | -21.38 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.09 | 0.11 | 0.13 | 0.15 | 0.16 |
| Current Ratio(x) | 5.08 | 3.61 | 3.33 | 3.76 | 3.34 |
| Quick Ratio(x) | 4.34 | 3.08 | 2.80 | 3.27 | 3.02 |
| Interest Cover(x) | 17.91 | 11.23 | 12.42 | 15.38 | 18.04 |
| Total Debt/Mcap(x) | 0.07 | 0.13 | 0.13 | 0.12 | 0.12 |
Compare Financial Ratios of peers of BLISS GVS PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BLISS GVS PHARMA | ₹1,693.2 Cr | 0.6% | 26.7% | 15.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹431,892.0 Cr | 3.7% | -3.2% | 46.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹166,129.0 Cr | 5.1% | 6.1% | 64% | Stock Analytics | |
| CIPLA | ₹121,231.0 Cr | 0.6% | -3.7% | 26.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,431.0 Cr | 1.9% | -3.4% | 5.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,639.9 Cr | 2.3% | -3.4% | 54% | Stock Analytics | |
BLISS GVS PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BLISS GVS PHARMA | 0.6% |
26.7% |
15.8% |
| SENSEX | 0.9% |
2% |
21% |
You may also like the below Video Courses
